Company: GNMSF
Filing Date: 2025-12-12
Form Type: SC TO-T/A
Source: 0001193125-25-316835
Chunk: 3

Company: GENMAB A/S
Filing Date: 2025-12-12
Form: SC TO-T/A
Chunk 3
---
 upon the terms and subject to the
conditions set forth in the Offer to Purchase. The procedures for accepting the Offer and tendering Common Shares during the Subsequent Offering Period are described in Section 3 — “Procedures for Accepting the Offer and Tendering Common Shares” of the Offer to Purchase and are generally the same as those applicable to the initial offering period, except that Common Shares validly tendered during the Subsequent Offering Period may not be withdrawn.

Pursuant to the terms of the Transaction Agreement, at the Closing, (i) Sven (Bill) Ante Lundberg, M.D., Mark Iwicki, Len
Kanavy, Paolo Pucci, Victor Sandor, M.D.C.M., and Jason Haddock each resigned and ceased to be directors of the Merus Board, (ii) Jan van de Winkel, Ph.D. became the executive director of the Merus Board and Chief Executive Officer of Merus,
(iii) Greg Mueller, Anthony Pagano and Martine van Vugt, Ph.D. each became a non-executive director of the Merus Board, and (iv) Anand Mehra, M.D. and Maxine Gowen, Ph.D. remained on the Merus Board
as independent directors.

Genmab and Purchaser expect to consummate the Back-End
Transactions pursuant to the Transaction Agreement beginning on the Subsequent Closing Date. Following the consummation of the Back-End Transactions, Merus will no longer be a public company, and the listing
of the Common Shares on the Nasdaq will be terminated. As a result, the Common Shares will cease to be publicly traded.

If you did not tender your Common Shares in the Offer and do not tender them during the Subsequent Offering Period, and the Back-EndTransactions are consummated, you will receive the same consideration for your Common Shares as Merus Shareholders who tendered their Common Shares in the Offer, which“ Back-EndCancellation Consideration” will be the Offer Consideration of $97.00 per Common Share, less any applicable withholding taxes and without interest. No Dutch dividend withholding tax ( dividendbelasting ) is applicable to amounts paid for Common Shares tendered in the Offer or during the Subsequent Offering Period. The withholding tax applicable to the Back-EndCancellation Consideration will include a fifteen percent (15%) Dutch dividend withholding tax to the extent the Back-EndCancellation Consideration per New TopCo Shares A exceeds the average paid up capital recognized for Dutch